Abstract: One new NNRTI (Y181C) mutation was identified and three patients taking PI-based regimens developed NRTI mutations (M184 V, M184I, and T215Y).
Transmission dynamics of HIV-1 subtype B in the Basque Country, Spain.
PMID: 26921800
2016
Infection, genetics and evolution
Abstract: The most prevalent mutations for each inhibitor class were PI L90M, NRTI T215D/Y/F, and NNRTI K103N, which were also among the most prevalent resistant variants in the whole dataset.
The Antiviral Activity of Approved and Novel Drugs against HIV-1 Mutations Evaluated under the Consideration of Dose-Response Curve Slope.
Abstract: Predominant DRAMs at RT genes were M184V, T215Y, M41L and V108I and H221Y while at PR genes were M46I and I47V.
Deep Sequencing of HIV-1 RNA and DNA in Newly Diagnosed Patients with Baseline Drug Resistance Showed No Indications for Hidden Resistance and Is Biased by Strong Interference of Hypermutation.
PMID: 27076656
2016
Journal of clinical microbiology
Abstract: Despite focused selection of patients with T215 revertants or singleton mutations, deep sequencing failed to identify the resistant T215Y/F or M184V or any other resistance mutation, indicating that in most of these cases there is no hidden resistance and that the virus detected at diagnosis by population sequencing is the original infecting variant.
Rapid and Simultaneous Detection of Major Drug Resistance Mutations in Reverse Transcriptase Gene for HIV-1 CRF01_AE, CRF07_BC and Subtype B in China Using Sequenom MassARRAY(R) System.
Abstract: In terms of loci, the detection rate of the alleles was greater than 97% for M41L, K65R, M184V and G190A, 91.2% for K101E/Q/P, 91.2% for T215F/Y, 89.9% for K103N/S and 80.5% for L210W.
Introduction: In this study, we established a multiplex assay for detecting the drug resistance mutations at 8 loci (M41L, K65R, K101E/Q/P, K103N/S, M184V, G190A, L210W an
Table: T215F/Y
HIV-1 Antiretroviral Drug Resistance Mutations in Treatment Naive and Experienced Panamanian Subjects: Impact on National Use of EFV-Based Schemes.
Abstract: The nucleoside reverse transcriptase inhibitor (NRTI) mutation M184V was more frequent in ARV drug-experienced individuals, while T215YFrev and M41L were more frequent in ARV drug-naïve subjects.
Discussion: In addition, T215F/Y confers high-level resistance to AZT and d4T and varying degrees of resistance to most NRTIs.
Discussion: In our study, the most frequent NRTIs associated mutation was M184V (76%), followed by T215F/Y (26.8%).
Discussion: Intermediate to high resistance levels to NRTIs in the ARV drug-experienced subjects were reported in Panama in previous years (2004-2005) and were associated to mutations L74V (2.4%),
Treatment Outcomes and Resistance Patterns of Children and Adolescents on Second-Line Antiretroviral Therapy in Asia.
PMID: 27355415
2016
Journal of acquired immune deficiency syndromes (1999)
Result: NRTI mutations included >=1 TAM (40%), >=4 TAMs (10%), T215Y/F (23%), Q151M (4%), M184V (56%), K65R (2%).
Result: Of the 156 (56%) children who had available resistance testing at the time of first-line failure, mutations included M184V (82%), >=1 thymidine analog mutation (TAM; 64%), >=4 TAMs (18%), T215Y/F (43%), K65R (10%), >=1 NNRTI mutation (92%), Y181I/C (44%), G190A (33%), K103N/S (27%), and V108I (15%); 30 (19%) children had DUET weighted scores >=4 (Table 2).
Surveillance of HIV Transmitted Drug Resistance in Latin America and the Caribbean: A Systematic Review and Meta-Analysis.
Result: Although no significant change was observed in NRTI TDR prevalence, a significant decrease in the frequency of M41L (p = 0.04), T215Y (p = 0.008), and K70R (p = 0.046) mutations was observed (Fig 7).
Result: The overall decrease in NRTI TDR was associated with a significant decrease in the frequency of M184V (p = 0.03) and the thymidine analog mutations (TAMs) K70R (p<0.0001) and T215Y (p = 0.007) (Fig 2).
Result: This decreasing trend was associated with reductions in frequency of several DR mutations including D67N, K70R, M184V, L210W,
Antiviral Activity of Bictegravir (GS-9883), a Novel Potent HIV-1 Integrase Strand Transfer Inhibitor with an Improved Resistance Profile.
PMID: 27645238
2016
Antimicrobial agents and chemotherapy
Method: The virus 6TAMs, containing six resistance mutations in HIV-1 RT (M41L, D67N, K70R, L210W, T215Y, and K219Q) that confer resistance to thymidine analogs, was constructed by cloning a PCR-amplified RT-encoding fragment from HIV-infected patient-derived plasma.
HIV mutation literature information.
PMID: 
2016
HIV clinical trials
Browser Board
Co-occurred Entities
Filtrator
ViMRT